HARRISBURG, Pa. (AP) — A Pennsylvania House majority is giving approval to a proposal to require the burial or cremation of fetal remains that end up in possession of a health care facility. The bill, modeled on Indiana legislation that was upheld by the U.S. Supreme Court earlier this year, was sent to the state Senate on a vote of 123 to 76. Supporters framed it as giving parents greater say in the disposal of remains, while opponents argued it would harass abortion facilities and impinge on women’s health choices.

The latest report from AARP shows family caregivers in Pennsylvania are providing $18.2 billion in unpaid care to family or friends at home. Andrea Sears reports…

HARRISBURG, Pa. (AP) — Gov. Tom Wolf will sign legislation allowing hunting on three Sundays a year in Pennsylvania. The Senate voted 38-11 on Wednesday. The bill permits Sunday hunting one day during rifle deer season, one during statewide archery deer season and a third day the Game Commission selects. The long-fought issue overcame opposition from farmers and outdoors groups. Pennsylvania has banned Sunday hunting since the 19th century, although there are currently several exceptions.

(Photo taken by Sandy Giordano)

The Center Volunteer Fire Department has been awarded a grant from Energy Transfer. Beaver County Radio News Correspondent Sandy Giordano has more. Click on ‘play’ to hear Sandy’s report…

WEATHER FORECAST FOR TUESDAY, NOV. 19TH, 2019

TODAY – CLOUDY. HIGH – 46.

TONIGHT – OVERCAST. LOW – 34.

WEDNESDAY – CLOUDY. HIGH – 44.

New, old drugs may offer fresh ways to fight heart disease
By MARILYNN MARCHIONE AP Chief Medical Writer
PHILADELPHIA (AP) — Novel drugs may offer fresh ways to reduce heart risks beyond the usual medicines to lower cholesterol and blood pressure.
One new study found that heart attack survivors benefited from a medicine long used to treat gout. Several experimental drugs also showed early promise for interfering with heart-harmful genes without modifying the genes themselves — in one case, with treatment just twice a year.
The research was featured at an American Heart Association conference ending Monday in Philadelphia.
“There’s a lot of excitement” about the new gene-targeting medicines, especially because they seem to last so long, said Dr. Karol Watson, of the University of California, Los Angeles.
Scientists have been exploring gene therapy — altering DNA — to attack the root cause of many diseases. The new drugs essentially accomplish the same thing without tampering with genes, said the University of Pennsylvania’s Dr. Daniel Rader, who has consulted for some makers of these drugs.
The medicines work by silencing or blocking messages that genes give to cells to make proteins that can do harm, such as allowing cholesterol to accumulate. The first few of these “RNA-interference” drugs recently were approved for other conditions, and research is also targeting heart disease.
Farthest along is inclisiran, tested in 1,561 people with heart disease from clogged arteries who still had high LDL, the bad form of cholesterol, despite taking standard drugs. They were given a shot of inclisiran or a dummy drug when they joined the study, three months later and then every six months.
The drug lowered LDL by 56% without serious side effects. More testing will show whether it also lowers heart attacks and other problems, not just cholesterol. Inclisiran’s maker, The Medicines Company, plans to seek federal approval for it later this year.
Two other RNA interference drugs aim at a different target — triglycerides, another fat in the blood that’s elevated in one quarter of Americans. Treatments include very low-fat diets, weight loss, fish oil and drugs, but doctors say more and better therapies are needed.
Each RNA interference drug was tested at various doses in 40 people. A single shot lowered triglycerides by 30% to 67%, and the benefit lasted for at least four months. The studies were just intended to show safety; Arrowhead Pharmaceuticals is developing both drugs.
Other research found new benefits from older drugs. AstraZeneca’s Farxiga, originally developed to treat diabetes, also lowered the risk of heart problems in heart failure patients who did not have diabetes. Among 2,605 of such patients treated for 18 months, about 9% of those on Farxiga had worsening heart failure or heart-related death versus nearly 13% of those not given the drug. That worked out to a 27% lower risk, without extra serious side effects.
Surprising benefits also were seen in a Canadian study of the decades-old gout drug. The anti-inflammatory drug colchicine — sold as Colcrys, Mitigare and in generic form — was tested in 4,745 people who recently had a heart attack.
After about two years, colchicine users had a 23% lower risk of suffering a new heart attack, heart-related death, stroke, cardiac arrest or urgent need for an artery-opening procedure compared with a group given dummy pills. The benefit came mostly from preventing strokes and artery-opening procedures, and some heart doctors would rather have seen more difference in heart attacks and deaths.
Colchicine is being tested in several other studies, and more evidence is needed before using it routinely to lower heart risks, Dr. L. Kristin Newby of Duke University wrote in a commentary published with the study in the New England Journal of Medicine.
Dr. Donald Lloyd-Jones, a Northwestern University cardiologist and program chief for the heart conference, was more supportive.
“When you have a safe drug that’s easily available, it’s going to be hard to hold this one back,” he said.
___
Marilynn Marchione can be followed on Twitter at http://twitter.com/MMarchioneAP
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Police chief: 3 people killed in Oklahoma Walmart shooting
By SEAN MURPHY Associated Press
DUNCAN, Oklahoma (AP) — Two men and a woman were fatally shot Monday morning outside a Walmart store in southwestern Oklahoma, and the shooter is among the dead, authorities said.
Two victims were shot inside a car and the third was in the parking lot outside the store in Duncan, Police Chief Danny Ford said.
Two bodies covered with sheets were visible in the parking lot Monday afternoon. One body was in the driver’s seat of a red, two-door car. The other body was lying on the ground next to the vehicle.
Bullet holes were visible in the car’s windshield. Police said in a Facebook post that a handgun was found at the scene.
Authorities have not identified those killed, but Stephens County District Attorney Jason Hicks has confirmed that the shooter was among the dead.
Authorities from multiple agencies including the Oklahoma State Bureau of Investigation, the state highway patrol and the Stephens County sheriff’s office were investigating the scene.
Police are also looking for witnesses to the shooting, Ford said.
Aaron Helton, of Duncan, said he was parking outside the Walmart where he planned to buy groceries when he heard about nine gunshots.
“I arrived and there were three bodies,” Helton said.
No staff members were involved in the shooting and the store was not evacuated, Walmart spokeswoman LeMia Jenkins said in an email.
“This was an isolated incident in the parking lot and was not an active shooter situation,” Jenkins said.
Duncan is about 80 miles (130 kilometers) south of Oklahoma City. The Walmart is in a commercial center that includes a sporting goods store and a dollar store along U.S. Highway 81, the main road that passes through Duncan heading south toward Texas.
___
Associated Press reporter Cedar Attanasio in El Paso, Texas, contributed to this report.